OncLive TV

Nathan A. Pennell, MD, PhD, discusses the underutilization of genetic testing in lung cancer.

Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.

Jyoti D. Patel, MD, discusses current immunotherapy options in stage IV non–small cell lung cancer.

Simon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.

Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, Penn Medicine, University of Pennsylvania, discusses promising targets in multiple myeloma.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Humberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Adam J. Waxman, MD, MS, discusses the STORM trial and using selinexor to treat patients with multiple myeloma.

Phillip J. Koo, MD, discusses next-generation imaging tools in prostate cancer.

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Rupal S. Bhatt, MD, PhD, discusses the potential identification of a pathway of resistance for PD-L1 in renal cell carcinoma.

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Daniela Molena, MD, discusses factors that determine if a patient with non–small cell lung cancer is eligible for surgical resection.

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.